|
1
|
Martin J and Rusch V: Lung neoplasms.
Surgery: Scientific Principles and Clinical Practice. Greenfield L,
Mullholland M, Oldham K, Zelenock G and Lillemoe K: Lippincott
Williams and Wilkins; Philadelphia, PA: pp. 1373–1400. 2001
|
|
2
|
Sica A, Allavena P and Mantovani A: Cancer
related inflammation: the macrophage connection. Cancer Lett.
267:204–215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP,
Wu C and Zheng L: Activated monocytes in peritumoral stroma of
hepatocellular carcinoma foster immune privilege and disease
progression through PD-L1. J Exp Med. 206:1327–1337. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sica A and Bronte V: Altered macrophage
differentiation and immune dysfunction in tumor development. J Clin
Invest. 117:1155–1166. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marigo I, Dolcetti L, Serafini P,
Zanovello P and Bronte V: Tumor-induced tolerance and immune
suppression by myeloid derived suppressor cells. Immunol Rev.
222:162–179. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haverkamp JM, Crist SA, Elzey BD, Cimen C
and Ratliff TL: In vivo suppressive function of myeloid-derived
suppressor cells is limited to the inflammatory site. Eur J
Immunol. 41:749–759. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ikushima H and Miyazono K: TGFβ
signalling: a complex web in cancer progression. Nat Rev Cancer.
10:415–424. 2010.
|
|
8
|
Calon A, Espinet E, Palomo-Ponce S, et al:
Dependency of colorectal cancer on a TGF-beta-driven program in
stromal cells for metastasis initiation. Cancer Cell. 22:571–584.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sansone P and Bromberg J: Targeting the
interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol.
30:1005–1014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maniati E, Soper R and Hagemann T: Up for
Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene.
29:5653–5662. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Donin N, Jurianz K, Ziporen L, Schultz S,
Kirschfink M and Fishelson Z: Complement resistance of human
carcinoma cells depends on membrane regulatory proteins, protein
kinases and sialic acid. Clin Exp Immunol. 131:254–263. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bubeck D, Roversi P, Donev R, Morgan BP,
Llorca O and Lea SM: Structure of human complement C8, a precursor
to membrane attack. J Mol Biol. 405:325–330. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Walport MJ: Complement. First of two
parts. N Engl J Med. 344:1058–1066. 2001.PubMed/NCBI
|
|
14
|
Walport MJ: Complement. Second of two
parts. N Engl J Med. 344:1140–1144. 2001.PubMed/NCBI
|
|
15
|
Boross P and Leusen JH: Boosting antibody
therapy with complement. Blood. 119:5945–5947. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ross GD, Vetvicka V, Yan J, Xia Y and
Vetvicková J: Therapeutic intervention with complement and
beta-glucan in cancer. Immunopharmacology. 42:61–74. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Markiewski MM, DeAngelis RA, Benencia F,
et al: Modulation of the antitumor immune response by complement.
Nat Immunol. 9:1225–1235. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li F, Cheng Y, Lu J, Hu R, Wan Q and Feng
H: Photodynamic therapy boosts anti-glioma immunity in mice: a
dependence on the activities of T cells and complement C3. J Cell
Biochem. 112:3035–3043. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Blok VT, Daha MR, Tijsma O, et al: A
bispecific monoclonal antibody directed against both the
membrane-bound complement regulator CD55 and the renal
tumor-associated antigen G250 enhances C3 deposition and tumor cell
lysis by complement. J Immunol. 160:3437–3443. 1998.
|
|
20
|
Oner F, Savaş I and Numanoğlu N:
Immunoglobulins and complement components in patients with lung
cancer. Tuberk Toraks. 52:19–23. 2004.PubMed/NCBI
|
|
21
|
Zimmermann-Nielsen E, Iversen LH, Svehag
SE, Thorlacius-Ussing O and Baatrup G: Activation capacity of the
alternative and classic complement pathways in patients operated on
for colorectal cancer. Dis Colon Rectum. 45:544–553. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saito T, Kuwahara A, Kinoshita T, et al:
Increases in immunoglobulin and complement in patients with
esophageal or gastric cancer. Surg Today. 22:537–542. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Espinosa E, Feliu J, Zamora P, et al:
Serum albumin and other prognostic factors related to response and
survival in patients with advanced non-small cell lung cancer. Lung
Cancer. 12:67–76. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takigawa N, Segawa Y, Okahara M, et al:
Prognostic factors for patients with advanced non-small cell lung
cancer: univariate and multivariate analyses including recursive
partitioning and amalgamation. Lung Cancer. 15:67–77. 1996.
View Article : Google Scholar
|
|
25
|
Yee J, Sadar MD, Sin DD, et al: Connective
tissue-activating peptide III: a novel blood biomarker for early
lung cancer detection. J Clin Oncol. 27:2787–2792. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhong L, Coe SP, Stromberg AJ, Khattar NH,
Jett JR and Hirschowitz EA: Profiling tumor-associated antibodies
for early detection of non-small cell lung cancer. J Thorac Oncol.
1:513–519. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qiu J, Choi G, Li L, et al: Occurrence of
autoantibodies to annexin I, 14-3-3 theta and LAMR1 in
prediagnostic lung cancer sera. J Clin Oncol. 26:5060–5066. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Trinchieri G: Cancer and inflammation: an
old intuition with rapidly evolving new concepts. Annu Rev Immunol.
30:677–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lucas SD, Karlsson-Parra A, Nilsson B, et
al: Tumor-specific deposition of immunoglobulin G and complement in
papillary thyroid carcinoma. Hum Pathol. 27:1329–1335. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Blok VT, Daha MR, Tijsma OM, Weissglas MG,
van den Broek LJ and Gorter A: A possible role of CD46 for the
protection in vivo of human renal tumor cells from
complement-mediated damage. Lab Invest. 80:335–344. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Varga L, Czink E, Miszlai Z, et al: Low
activity of the classical complement pathway predicts short
survival of patients with chronic lymphocytic leukaemia. Clin Exp
Immunol. 99:112–116. 1995. View Article : Google Scholar
|
|
32
|
Klos A, Tenner AJ, Johswich KO, Ager RR,
Reis ES and Köhl J: The role of the anaphylatoxins in health and
disease. Mol Immunol. 46:2753–2766. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Visser KE, Korets LV and Coussens LM:
Early neoplastic progression is complement independent. Neoplasia.
6:768–776. 2004.PubMed/NCBI
|
